

Original Article

Does ibuprofen treatment in patent ductus arteriosus alter oxygen free radicals in premature infants?

Melek Akar, Tulin G. Yildirim, Gonca Sandal, Senol Bozdog, Omer Erdeve, Nahide Altug, Nurdan Uras, Serife S. Oguz, Ugur Dilmen

Zekai Tabir Burak Maternity Teaching Hospital, Neonatal Intensive Care Unit, Ankara, Turkey

Abstract *Introduction:* Ibuprofen is used widely to close patent ductus arteriosus in preterm infants. The anti-inflammatory activity of ibuprofen may also be partly due to its ability to scavenge reactive oxygen species and reactive nitrogen species. We evaluated the interaction between oxidative status and the medical treatment of patent ductus arteriosus with two forms of ibuprofen. *Materials and methods:* This study enrolled newborns of gestational age ≤ 32 weeks, birth weight ≤ 1500 g, and postnatal age 48–96 hours, who received either intravenous or oral ibuprofen to treat patent ductus arteriosus. Venous blood was sampled before ibuprofen treatment from each patient to determine antioxidant and oxidant concentrations. Secondary samples were collected 24 hours after the end of the treatment. Total oxidant status and total antioxidant capacity were measured using Erel's method. *Results:* This prospective randomised study enrolled 102 preterm infants with patent ductus arteriosus. The patent ductus arteriosus closure rate was significantly higher in the oral ibuprofen group (84.6 versus 62%) after the first course of treatment ($p = 0.011$). No significant difference was found between the pre- and post-treatment total oxidant status and total antioxidant capacity in the groups. *Discussion:* Ibuprofen treatment does not change the total oxidant status or total antioxidant capacity. We believe that the effect of ibuprofen treatment in inducing ischaemia overcomes the scavenging effect of ibuprofen.

Keywords: Ibuprofen; patent ductus arteriosus; prematurity; oxidative stress

Received: 17 January 2016; Accepted: 29 April 2016; First published online: 20 June 2016

REACTIVE OXYGEN SPECIES, WHICH ARE OXYGEN-derived metabolites, are produced in organisms in balanced amounts. When produced in excess, they are responsible for tissue damage, called oxidative stress. The antioxidative defence system involves several enzymes and molecules with antioxidant capabilities that protect the organism against free radicals.^{1–3}

Preterm infants are especially prone to oxidative stress. They are very often exposed to high oxygen concentrations and are more prone to infections. Compared with healthy adults, newborn infants have lower plasma levels of antioxidants such as vitamin E,

β -carotene, and sulphhydryl groups, lower plasma levels of metal-binding proteins including ceruloplasmin and transferrin, and reduced erythrocyte superoxide dismutase activity. These can all increase reactive oxygen species accumulation and the utilisation and depletion of antioxidative agents.⁴ Oxidative stress in preterm infants damages several organs and can cause chronic lung disease, retinopathy of prematurity, necrotising enterocolitis, and patent ductus arteriosus.^{5–8}

Postnatal regulation of the ductus arteriosus depends on a balance between oxygen-induced contraction and prostaglandin-induced relaxation.⁹ It has been hypothesised that reactive oxygen metabolites play an important role in ductus regulation.¹⁰

Ibuprofen primarily inhibits prostaglandin production and inflammatory events, and it is widely

Correspondence to: M. Akar, MD, Tepecik Eğitim ve Araştırma Hastanesi, Yenidoğan Kliniği Konak, İzmir, Turkey. Tel: +90 505 255 05 18; Fax: +90 232 433 07 56; E-mail: melek_akar@yahoo.com.tr

used to close patent ductus arteriosus. It has been postulated that the anti-inflammatory activity of ibuprofen is partly due to its ability to scavenge reactive oxygen species and nitrogen reactive species when oxidative stress occurs.¹¹

We performed a prospective, randomised study to evaluate the interaction between oxidative status and the medical treatment of patent ductus arteriosus with different forms of ibuprofen.

Materials and methods

Setting and participants

The present study was conducted in the Neonatal Intensive Care Unit of Zekai Tahir Burak Maternity Teaching Hospital between January 2009 and February 2010. This trial was approved by the local ethics committee, and the infants were enrolled in the study after obtaining written parental consent.

This study enrolled preterm infants of gestational age ≤ 32 weeks, birth weight ≤ 1500 g, and postnatal age of 48–96 hours who received either intravenous or oral ibuprofen for patent ductus

arteriosus. The echocardiographic criteria for haemodynamically significant patent ductus arteriosus were ductal diameter >1.5 mm, ratio of the left atrium to the aortic root >1.5 , and diastolic aortic retrograde flow.¹²

During the study period, 376 very low birth weight preterm infants of gestational age ≤ 32 weeks were admitted to our neonatal intensive care unit. Of the 144 very low birth weight preterm infants who had significant patent ductus arteriosus, 36 were excluded before enrolment for various reasons (Fig. 1). Patients were randomly assigned to treatment groups using cards in sealed opaque envelopes, and 102 patients completed the study protocol. Group sample sizes of 50 in the intravenous group and 52 in the oral group achieved 94% power to detect a difference of 0.2650 in group proportions depending on the closure rate.

Study design

Enrolled patients received either intravenous or oral ibuprofen at an initial dose of 10 mg/kg, followed by




Figure 1.
Flow chart of the study.

two doses of 5 mg/kg each after 24 and 48 hours. Venous blood was sampled before ibuprofen treatment from each patient to determine antioxidant and oxidant concentrations. The second set of samples was collected 24 hours after the end of the treatment. The samples were centrifuged at 1500g for 10 minutes within 30 minutes of collection, stored at -80°C , and analysed within 3 months. Total antioxidant capacity levels were measured using Erel's total antioxidant capacity method, which is based on bleaching the characteristic colour of a more stable 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) radical cation by antioxidants.¹³ The results are expressed in mmol Trolox equivalents/L. The serum thiol (total SH group) content was measured using dithionitrobenzoic acid. Total oxidant status serum concentrations were measured using Erel's total oxidant status method, which is based on the oxidation of ferrous ion to ferric ion in the presence of various oxidative species in acidic medium and measurement of the ferric ion using xylenol orange.¹⁴ The results are expressed in $\mu\text{mol H}_2\text{O}_2/\text{L}$. Erel's total antioxidant capacity and total oxidant status methods are colorimetric and automated; the precision of this assay is excellent, $<3\%$. The ratio of total oxidant status to total antioxidant capacity was regarded as an oxidative stress index. To perform the calculation, the units for total antioxidant capacity (mmol Trolox equivalents/L) were changed to $\mu\text{mol Trolox equivalents/L}$, and the oxidative stress index value was calculated as follows: oxidative stress index = [total oxidant status $\mu\text{mol/L}$]/(Total antioxidant capacity $\mu\text{mol/L}$)/100].¹²⁻¹⁴

The major outcome of the present study was the effect of different forms of ibuprofen treatment on the antioxidant and oxidant status of the patients.

Secondary outcomes were the relationship between pre-treatment total antioxidant capacity and total oxidant status levels and the success rate of patent ductus arteriosus closure.

Statistical analysis

The data are presented as mean \pm standard deviation, frequencies, or percentages. Paired samples *t*-tests and independent-samples *t*-tests were used for continuous variables, and the χ^2 test was used for categorical variables; $p < 0.05$ was considered statistically significant. The statistical analyses were performed using SPSS 16.0 for Windows (SPSS, Chicago, Illinois, United States of America).

Results

The baseline characteristics including birth weight, gestational age, gender, and prenatal, natal, and postnatal data were similar in the two groups (Table 1).

After the first course of treatment, the patent ductus arteriosus was closed in 46 (84.6%) of the patients assigned to the oral ibuprofen group versus 31 (62%) of those enrolled to the intravenous ibuprofen group ($p = 0.011$).

We evaluated the TOS between PDA closed and non-closed patients before ibuprofen treatment. The serum levels of oxidative status before treatment between groups did not differ significantly ($p = 0.29$). We observed that oxidative status did not influence the response to ibuprofen therapy.

The total antioxidant capacity and total oxidant status before and after the treatment did not differ

Table 1. Demographic data of both groups.

	Oral ibuprofen (n = 52)	Intravenous ibuprofen (n = 50)	p
Mean birth weight (g)	1170 \pm 297	1205 \pm 366	0.59
Mean gestational age (weeks)	28.5 \pm 1.9	28.7 \pm 2.1	0.652
Birth weight distribution [n (%)]			
<750 g	12 (23.1%)	13 (26%)	
750–1000 g	18 (34.6%)	14 (28%)	0.624
>1000 g	22 (42.3%)	23 (46%)	
Gestational age distribution [n (%)]			
<28 weeks	4 (7.7%)	5 (10%)	
28–30 weeks	8 (15.4%)	14 (28%)	0.238
>30 weeks	40 (76.9%)	31 (62%)	
Gender (male/female)	22/30	29/21	0.11
Antenatal steroid use [n (%)]	30 (57.7%)	26 (52%)	0.56
Prolonged premature rupture of membrane [n (%)]	11 (21.2%)	8 (16%)	0.504
Delivery by caesarean section [n (%)]	50 (96.2%)	47 (94%)	0.964
Resuscitation in delivery room [n (%)]*	29 (55.8%)	27 (54%)	0.858
Surfactant for respiratory distress syndrome [n (%)]	32 (61.5%)	30 (60%)	0.874
Caffeine use during first 3 days [n (%)]	48 (92.3%)	42 (84%)	0.193

*Positive pressure ventilation

Table 2. Evaluation of TAC, TOC, and OSI levels after treatment in each group and between groups.

	Oral ibuprofen (n = 52)			Intravenous ibuprofen (n = 50)			p*	p**
	Before treatment	After treatment	p	Before treatment	After treatment	p		
TAC (Trolox equiv/L)	1.7 ± 0.27	1.69 ± 0.3	0.057	1.69 ± 0.3	3.07 ± 7.9	0.23	0.82	0.22
TOS (µmol H ₂ O ₂ /L)	26.9 ± 17.4	30.0 ± 23.07	0.302	27.4 ± 24.21	30.4 ± 20.9	0.47	0.89	0.93
OSI (Arbitrary unit)	0.15 ± 0.09	0.16 ± 0.10	0.36	0.18 ± 0.27	0.18 ± 0.14	0.95	0.45	0.46

OSI = oxidative stress index; SD = standard deviation; TAC = total antioxidant capacity; TOS = total oxidation status mean ± SD

*p value for before treatment measurements between groups

**p value for after treatment measurements between groups

significantly between groups. In addition, there was no significant difference between the groups in pre- and post-treatment total antioxidant capacity or total oxidant status (Table 2).

Discussion

This study examined changes in total antioxidant capacity and total oxidant status after oral and intravenous ibuprofen treatments. To our knowledge, this is the first study to evaluate the antioxidant and oxidant status in preterm infants after ibuprofen treatment for patent ductus arteriosus. We hypothesised that after constriction of the ductus, no reactive oxygen species would be produced by the ductus in amounts that would affect the vessel; however, we found that the total antioxidant capacity and total oxidant status did not change after ibuprofen treatment.

Chemically generated oxygen metabolites can produce relaxation of the ductus arteriosus and inhibit oxygen-induced contraction. These effects work through the production of prostaglandin E₂.¹⁵ Prostaglandin synthase is an important source of oxidants that plays a role in regulating the ductus. The ductus arteriosus is very sensitive to the vasodilating action of prostaglandin E₂, which opposes oxygen-induced contraction of the ductus.^{16,17} There are many ways by which reactive oxygen species might affect vascular tone. Meerson et al¹⁸ suggested that oxygen radical effects are mediated by the “lipid triad” comprising lipid peroxidation, activation of lipases and phospholipases, and production of free fatty acids and lysophospholipids. Lipid peroxidation leads to an increase in membrane fluidity and permeability. Oxygen metabolites can also damage sodium–potassium ATPase.

Oxygen species can liberate arachidonic acid by stimulating the lipid peroxidation of cell membranes and activating phospholipase A. Both hydrogen peroxide and lipid hydroperoxides can accelerate cyclooxygenase activity and stimulate the production of prostaglandins E₂ and I₂ in ductus arteriosus.¹⁹

Pharmacological closure of a patent ductus arteriosus can occur with ibuprofen and indomethacin, which block the conversion of arachidonic acid into various prostaglandins.²⁰ Some studies have found that indomethacin is a weak scavenger and a weak inhibitor of free radical formation.²¹ Clyman et al²² showed that indomethacin blocked both the hydrogen peroxide-induced and hypoxanthine–xanthine oxidase-induced relaxation of the ductus; in addition, indomethacin reversed the increased rate of prostaglandin production and relaxation previously induced by hypoxanthine–xanthine oxidase. Hiller and Wilson²³ showed that various non-steroidal anti-inflammatory drugs could scavenge hydroxyl radicals. Subsequently, ketoprofen, ibuprofen, flurbiprofen, and naproxen were found to be effective hydroxyl radical scavengers.²⁴ Therapeutic concentrations of both ibuprofen and ketoprofen had potent scavenging effects. Costa et al²⁵ demonstrated that under experimental conditions many of the studied non-steroidal anti-inflammatory drugs showed reactive oxygen species scavenging activity. The observed effects may strongly contribute to the anti-inflammatory therapeutic activity observed with these non-steroidal anti-inflammatory drugs.

We prefer ibuprofen treatment for patent ductus arteriosus closure, because indomethacin treatment is associated with adverse reactions such as reduced renal, mesenteric, and cerebral perfusion.²⁶ We planned to observe the effects of ibuprofen on the total antioxidant capacity and total oxidant status levels using a different method. The primary mechanism of the anti-inflammatory action of ibuprofen is the inhibition of prostaglandin synthesis. It has also been suggested that the activity of ibuprofen is partly due to its ability to scavenge reactive oxygen species. These effects, which are usually obtained at high concentrations, are not important for the therapeutic effect.

The main limitation of our study was that the oral ibuprofen group had a larger number of older patients, although the difference between groups was not significant, and this may partially explain the improved efficacy of oral ibuprofen. A second

limitation of our study was that it would have been better to include a non-treatment, non-patent ductus arteriosus, group.

This study demonstrated that ibuprofen treatment did not change the total antioxidant capacity or total oxidant status in neonates. The following three factors may have affected our results. First, the inhibitory effects of ibuprofen on the production of oxygen free radicals are usually obtained at high concentrations. In our study, we used a therapeutic dosage of ibuprofen. Second, the effective concentrations in *in vitro* studies vary with the methodology used.²⁷ Our method – Erel's method – was different from methods used in previous studies. Third, and perhaps most important, may be the effects caused by ischaemia of the vessel wall after contraction of the ductus arteriosus. We know that constriction of the ductus produces ischaemia of the inner luminal one-third of the vessel wall.¹⁷ Ischaemia and tissue hypoxia can induce reactive oxygen metabolites. The mechanism of cellular injury after ischaemia is probably mediated by the generation of reactive oxygen species, which leads to a cascade of damaging events. We believe that after ibuprofen treatment the reactive oxygen metabolite-inducing effect of ischaemia blocked the scavenging effects of ibuprofen treatment.

Acknowledgements

None.

Financial Support

This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

Conflicts of Interest

None.

Ethics Standards

This trial was approved by the local ethics committee, and the infants were enrolled to the study only after obtaining written parental consent.

References

- Fridovich I. Oxygen toxicity: a radical explanation. *J Exp Biol* 1998; 201: 1203–1209.
- Gitto E, Reiter RJ, Karbownik M, et al. Causes of oxidative stress in the pre-and perinatal period. *Biol Neonat* 2002; 81: 146–157.
- Halliwell B. Free radicals, antioxidants and human disease: curiosity, cause, or onsequence? *Lancet* 1999; 344: 721–724.
- Zydzorczyk C, Mitanchez D, Buffat C, et al. Oxidative stress after preterm birth: origins, biomarkers, and possible therapeutic approaches. *Arch Pediatr* 2015; 22: 1047–1055.
- Sandal G, Mutlu B, Uras N, Erdev O, Oguz SS, Dilmen U. Evaluation of treatment with hydrocortisone on oxidant/antioxidant system in preterm infants with BPD. *Eur Rev Med Pharmacol Sci* 2013; 17: 2594–2597.
- Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. *Ophthalmology* 2015; 122: 200–210.
- Perrone S, Tataranno ML, Santacroce A, Negro S, Buonocore G. The role of oxidative stress on necrotizing enterocolitis in very low birth weight infants. *Curr Pediatr Rev* 2014; 10: 202–207.
- Inayat M, Bany-Mohammed F, Valencia A, et al. Antioxidants and biomarkers of oxidative stress in preterm infants with symptomatic patent ductus arteriosus. *Am J Perinatol* 2015; 32: 895–904.
- Clyman RI. Ductus arteriosus: current theories of prenatal and postnatal regulation. *Semin Perinatol* 1987; 46: 64–71.
- Clyman RI, Saugstad OD, Mauray F. Reactive oxygen metabolites relax the lamb ductus arteriosus by stimulating prostaglandin production. *Circ Res* 1989; 64: 1–8.
- Van Overmeire B, Chemtob S. The pharmacologic closure of the patent ductus arteriosus. *Semin Fetal Neonatal Med* 2005; 10: 1777–1884.
- Noori S. Patent ductus arteriosus in the preterm infant: to treat or not to treat? *J Perinatol* 2010; 30: 31–37.
- Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. *Clin Biochem* 2004; 37: 112–119.
- Erel O. A new automated colorimetric method for measuring total oxidant status. *Clin Biochem* 2005; 38: 1103–1111.
- Majed BH, Khalil RA. Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. *Pharmacol Rev* 2012; 64: 540–582.
- Coceani F, Baragatti B. Mechanisms for ductus arteriosus closure. *Semin Perinatol* 2012; 36: 92–97.
- Reese J. Patent ductus arteriosus: mechanisms and management. *Semin Perinatol* 2012; 36: 89–91.
- Meerson FZ, Kagan VE, Kozlov YP, Belkina LM, Arkhipenko YV. The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart. *Basic Res Cardiol* 1982; 77: 465–485.
- Coceani F, Jhamandas VM, Bodach E, Labuc J, Olley PM, Borgeat P. Evidence against a role for lipoxygenase-derived products of arachidonic acid in the lamb ductus arteriosus. *Can J Physiol Pharmacol* 1982; 60: 345–349.
- Pacifici GM. Clinical pharmacology of ibuprofen and indomethacin in preterm infants with patent ductus arteriosus. *Curr Pediatr Rev* 2014; 10: 216–237.
- Vapaatalo H. Free radicals and antiinflammatory drugs. *Med Biol* 1986; 64: 1–7.
- Clyman RI, Saha S, Jobe A, Oh W. Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomised controlled trials on clinical practice. *J Pediatr* 2007; 150: 46–50.
- Hiller KO, Wilson RL. Hydroxyl-free radicals and anti-inflammatory drugs: biological inactivation studies and reaction rate constants. *Biochem Pharmacol* 1983; 32: 2109–2111.
- Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, Kohno M, Ogawa N. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. *J Neurochem* 2001; 76: 1895–1904.
- Costa D, Moustinho L, Fontes JL, Costa Lima C, Fernandes E. Antioxidant activity and inhibition of human neutrophil oxidative burst mediated by arylpropionic acid non-steroidal anti-inflammatory drugs. *Biol. Pharm Bull* 2006; 29: 1659–1670.
- Oncel MY, Erdev O. Safety of therapeutics used in management of patent ductus arteriosus in preterm infants. *Curr Drug Saf* 2015; 10: 106–112.
- Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. *Pharmazie* 2003; 58: 447–474.